DREAMM-10
Phase 3 Clinical Trial Comparing the Safety and Efficacy of Belantamab Mafodotin, Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplant
What will happen during the trial?
In DREAMM-10, the study drug (belantamab mafodotin) will be combined with 2 drugs already approved to treat multiple myeloma, lenalidomide and dexamethasone. Everyone in the study will take these 2 standard drugs, but some will also take, daratumumab, instead of belantamab mafodotin. Daratumumab, also approved for multiple myeloma, will serve as the ‘control’, which means the study drug (belantamab mafodotin) will be compared to it.
After screening to check if DREAMM-10 is a good fit, participants will be randomly assigned (as if by the flip of a coin, or a 50/50 chance) To 1 of the 2 treatment “arms” (groups).
Depending on your treatment arm, you will get intravenous (IV, through a vein in your arm) treatment or subcutaneous injection (needle beneath the skin). Both groups will also take capsules and tablets by mouth.
You may continue to receive treatment unless your multiple myeloma gets worse or you have unwanted side effects or choose to discontinue participation.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 520 patients (estimated)
- Sponsors
- GlaxoSmithKline
- Tags
- Antibody Drug Conjugate (ADC), B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2027
- NCT Identifier
- NCT06679101
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.